FDA clears 20 ZYN pouches for modified-risk claim

Philip Morris International Inc. said on June 30, 2026 that the U.S. Food and Drug Administration issued Modified Risk Tobacco Product orders for 20 variants of its ZYN nicotine pouch products, a regulatory milestone that could support U.S. commercialization and brand messaging.

FDA MRTP orders cover 20 ZYN variants

The company said the orders are the first MRTP authorizations granted for nicotine pouches. The authorization allows PMI’s U.S. business to market a specific claim for the covered products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke,” the company said.

The MRTP pathway is designed to permit reduced-risk or reduced-exposure claims for tobacco products when regulators determine the marketing is appropriate for the protection of public health. The company said the decision applies only to the authorized ZYN variants and the authorized claim.

For equities, the decision can be read as a de-risking event for the nicotine pouch category in the U.S., where tobacco and nicotine firms have been competing for growth as cigarette volumes decline. The extent of the upside will depend on execution, compliance constraints tied to the order, and any broader regulatory or legal challenges.

The next near-term catalyst is whether Philip Morris provides additional detail on commercial rollout and label or advertising requirements by July 31, 2026.